• We are a fully integrated vaccine company with two travel vaccines on the market.

  • Dedicated to innovation in vaccine research and development.

  • Valneva’s R&D focuses on vaccines addressing high unmet medical needs.

  • Valneva covers the full value chain from research to market.

Welcome to Valneva
A leading pure play vaccine company.

— February 23, 2017

Valneva Reports Strong Q4 and FY 2016 Business Performance; Expects Further Growth in Sales and EBITDA, R&D Progress in 2017

Read more

— Stock information


— December 9, 2016
Valneva Receives FDA and European Approvals to Start Clinical Testing of Lyme Disease Vaccine Candidate

Read more
— Financial Calendar

February 23, 2017
Preliminary 2016 Results (Revenues, Cash)

March 23, 2017
2016 Financial Statements

See all dates

KOL event in N.Y. on Lyme disease (webcast)



learn more
play video Valneva's CEO Thomas Lingelbach
comments on Group Strategy

– Upcoming conferences and fairs

Credit Suisse 2017 Global Healthcare Conference
London, UK
February 28, 2017

World Vaccine Congress
Washington, US
April 10-12, 2017

10th Kempen Life Sciences Conference
Amsterdam, NL
April 18-19, 2017

Please update your browser...